Anti-VEGF use for ROP is expanding beyond bevacizumab and ranibizumab, with aflibercept’s fusion-protein structure conferring ...

Japan MHLW grants marketing authorization to Bayer’s Eylea 8 mg to treat patients with macular edema following RVO: Berlin Tuesday, March 24, 2026, 13:00 Hrs [IST] The Ministry ...

Q16W dosing interval; Furthermore, nearly 60% of the participants held the potential to extend the dosing interval to ...

Intravitreal aflibercept 2 mg prefilled syringes are linked to larger delivery volumes and greater immediate IOP elevation.

When discussing how long Eylea stays in your system, it’s important to distinguish between how long the drug remains in your eye versus your bloodstream. According to the drug’s prescribing ...

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained ...

Executives from 4D Molecular Therapeutics (NASDAQ:FDMT) outlined the company’s gene therapy platform, clinical progress, and ...

Building on the success of GLOW1 and with all patients on a 6-month dosing interval, Zenkuda (tarcocimab tedromer) demonstrated superiority to sham with 62.5% of Zenkuda-treated patients achieving ...

Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoidApproval in ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...